[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,696,458
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 1.05
  • Price/Sales 9.39
  • Price/Cash Flow N/A
  • Price/Book 2.46

Options Overview Details

View History
  • Implied Volatility 75.02% (+1.92%)
  • Historical Volatility 64.62%
  • IV Percentile 63%
  • IV Rank 42.57%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 6) 2.92 (5.86%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 64,532
  • Volume Avg (30-Day) 41,810
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 714,875
  • Open Int (30-Day) 683,950
  • Expected Range 46.99 to 52.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.01
  • Number of Estimates 10
  • High Estimate $-1.32
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +5.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.90 +13.69%
on 06/02/26
53.06 -5.93%
on 05/13/26
-3.36 (-6.31%)
since 05/12/26
3-Month
43.68 +14.26%
on 05/01/26
59.48 -16.09%
on 05/11/26
-3.48 (-6.52%)
since 03/12/26
52-Week
22.28 +124.01%
on 11/21/25
59.55 -16.19%
on 03/04/26
+22.56 (+82.49%)
since 06/12/25

Most Recent Stories

More News
How to Play PBLS Stock After the Parabilis IPO

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.

KLRA : 18.89 (-3.33%)
PBLS : 27.26 (-10.06%)
MRNA : 49.91 (+0.54%)
3 Unpopular Stocks We Steer Clear Of

3 Unpopular Stocks We Steer Clear Of

NOV : 21.13 (+0.48%)
RPD : 7.14 (+0.14%)
MRNA : 49.91 (+0.54%)
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]

MRNA : 49.91 (+0.54%)
3 ETFs For the Coming Genomics Revolution

Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.

HELX.BZ : N/A (N/A)
IDNA : 29.77 (+0.85%)
MRNA : 49.91 (+0.54%)
ARKG.BZ : N/A (N/A)
Why Is Moderna (MRNA) Stock Rocketing Higher Today

Why Is Moderna (MRNA) Stock Rocketing Higher Today

MRNA : 49.91 (+0.54%)
Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

XLV : 153.81 (-0.18%)
LLY : 1,133.00 (-2.41%)
MRNA : 49.91 (+0.54%)
Moderna to Present at Upcoming Conference in June 2026

CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:

MRNA : 49.91 (+0.54%)
Option Volatility And Earnings Report For June 1-5

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.

CIEN : 445.98 (+0.17%)
MSFT : 390.74 (+0.10%)
AVGO : 382.07 (-0.91%)
CRWD : 682.80 (-1.26%)
TSLA : 406.43 (+1.82%)
MU : 981.61 (-1.43%)
MDT : 80.20 (-0.16%)
MRNA : 49.91 (+0.54%)
CRM : 165.89 (-0.34%)
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence...

MRK : 119.05 (-1.42%)
MRNA : 49.91 (+0.54%)
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation

MRNA : 49.91 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 53.36
2nd Resistance Point 52.56
1st Resistance Point 51.23
Last Price 49.91
1st Support Level 49.10
2nd Support Level 48.30
3rd Support Level 46.97

See More

52-Week High 59.55
Last Price 49.91
Fibonacci 61.8% 45.31
Fibonacci 50% 40.92
Fibonacci 38.2% 36.52
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.